Dacetuzumab: Phase IIb discontinued

Seattle Genetics discontinued the double-blind, international Phase IIb SeaGen MARINER trial after an IDMC determined during a planned interim analysis that dacetuzumab in combination with rituximab and ICE (ifosfamide/carboplatin/etoposide) chemotherapy would likely miss the primary endpoint of superior complete response rate vs. placebo plus rituximab and ICE. The trial had enrolled about two-thirds of the expected 224 patients. The company plans to present data from a Phase Ib trial of dacetuzumab in combination with Gemzar gemcitabine and rituximab for the indication at the American Society of Hematology meeting in New Orleans in December. ...